OL Oncology Letters 1792-1074 1792-1082 D.A. Spandidos 10.3892/ol.2019.10657 OL-0-0-10657 Articles Sonic hedgehog pathway mediates genistein inhibition of renal cancer stem cells LiEnlai 1 * ZhangTao 1 * SunXianchao 1 * LiYuan 2 * GengHao 1 YuDexin 1 ZhongCaiyun 2 Department of Urology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230032, P.R. China Department of Nutrition and Food Safety, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China Correspondence to: Professor Dexin Yu, Department of Urology, The Second Affiliated Hospital of Anhui Medical University, 80 Feicui Road, Hefei, Anhui 230032, P.R. China, E-mail: ay2fy_uro@126.com Professor Caiyun Zhong, Department of Nutrition and Food Safety, School of Public Health, Nanjing Medical University, 81 Tianyuan Road, Nanjing, Jiangsu 211166, P.R. China, E-mail: cyzhong@njmu.edu.cn

Contributed equally

 09 2019 24 07 2019 18 3 3081 3091 04072018 02052019 Copyright: © Li et al. 2019 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cancer stem cells (CSCs) have been implicated in the genesis, progression and recurrence of renal cancer. The sonic hedgehog (Shh) pathway serves a critical role in maintaining the stemness of CSCs. Genistein, a major isoflavone component extracted from soybeans and soy products, has been demonstrated to possess anticancer activity. However, the effects of genistein on renal CSCs and its underlying mechanisms remain to be fully elucidated. The aim of the present study was to investigate the role of the Shh pathway in genistein inhibition of renal CSCs. The results of the present study demonstrated that expression levels of renal CSC markers were markedly upregulated in the sphere-forming cells, which were isolated and enriched from 786-O and ACHN cells in a tumor sphere formation assay, and more cells were arrested at the G0/G1 phase instead of the S1 phase compared with the adherent cells. Furthermore, the present study demonstrated that genistein could effectively diminish the activity of renal CSCs by suppressing tumor sphere formation, decreasing renal CSCs markers, inhibiting proliferation and inducing apoptosis. Additionally, the downregulation of Shh pathway activity could inhibit renal CSCs. Genistein exhibited an inhibitory effect on renal CSCs by attenuating the activation of the Shh pathway. In conclusion, the results illustrated the role of the Shh pathway in regulating renal CSC traits and the intervention of renal CSCs by genistein, which could provide novel insights into the molecular mechanisms of renal CSC intervention.

 genistein renal cancer stem cells sonic hedgehog pathway inhibition renal carcinoma Introduction

Renal cancer is a deadly disease with a global annual incidence of 143,000 cases of cancer-associated mortality, with the 9th highest incidence rate in men and 14th highest in women, as reported in 2012 (1). Renal cell carcinoma (RCC) is the most common form of renal neoplasm, accounting for >90% of cases in adults regardless of sex, worldwide (1). The high metastatic rate of RCC and its resistance to traditional chemotherapy and radiotherapy results in an unpredictable presentation as well as adverse clinical outcomes. Although surgical treatment remains the gold standard for treating primary RCC, 30–40% patients may undergo progression or recurrence following the initial radical nephrectomy, and the 5-year survival rate of metastatic patients was only 12% in 2015 (2). Therefore, there is an urgent need to investigate novel approaches for treating RCC.

Cancer stem cells (CSCs), a minor initiating cell subpopulation within solid tumors, are associated with unique characteristics, including clonogenesis, high self-renewal capacity and multilineage differentiation properties (3). Emerging evidence has demonstrated that CSCs are implicated in tumorigenesis, progression, chemoresistance and relapse of malignancies (3–5). To date, CSCs have been isolated and identified in various types of solid malignancy or established cell lines, including glioblastoma, breast cancer and renal cancer (6–8). Bussolati et al (9) isolated renal CSCs from the tumor samples of patients with clear cell RCC using fluorescence-activated cell sorting in 2008. Subsequently, Zhong et al (10) enriched CSCs from the RCC cell line SK-RC-42 using a sphere-formation assay. In addition, Huang et al (11) identified a cancer stem-like cell side population in the 769P cell line. Therefore, understanding the biology of renal CSCs for selective targeting can be an effective interventional strategy in preventing and treating renal cancer.

The sonic hedgehog (Shh) pathway has been considered as an oncogenic pathway, serving a crucial role in the maintenance of tissue polarity and CSC properties (12). Aberrant activation of the Shh pathway has been reported to be involved in various types of human malignancy (13). The binding of hedgehog ligands, including Shh protein, to the transmembrane receptor patched 1 (PTCH) results in the activation of the Shh pathway. PTCH represses the activity of the transmembrane protein smoothened (Smo) in the absence of Shh protein, which can thereby activate an endocellular signal transduction cascade via the glioma-associated oncogene (Gli) transcription factor family, including Gli1, Gli2 and Gli3 (14). Gli1 acts as a transcription activator, while Gli2 and Gli3 can function either as repressors or activators depending on the context (14,15).

Recently, numerous studies have illustrated that dietary factors exert chemo-preventative functions and can decrease the risk of multiple types of cancer (16–18). Notably, certain botanical compounds can directly regulate CSC activity; compounds that have now been identified as promising anticancer and therapeutic agents. Among these compounds, genistein (4,5,7-trihydroxyisoflavone), a major isoflavone component that can be isolated from soybeans and soy products, possesses anticancer potential by targeting the CSCs of different tumors (19,20). Genistein exerts anticancer effects on various types of malignancy, including breast, colon and ovarian cancer (19,21,22). Additionally, it has been reported that genistein inhibits the pluripotency of prostate and gastric cancer cells by targeting the hedgehog-Gli1 pathway (20,23).

However, to the best of our knowledge, the anticancer properties of genistein against renal CSCs remain to be elucidated. Therefore, the aim of the present study was to evaluate the anticancer effects of genistein on renal CSCs, and to evaluate whether the Shh pathway may be involved in the genistein-induced anticancer activity. The findings of the present study may provide valuable avenues in the search for a potential interventional target of genistein in renal CSCs.

 Materials and methods <sec> <title>Chemicals and reagents

Genistein and DMSO were purchased from Sigma-Aldrich; Merck KGaA. Vismodegib and purmorphamine were purchased from MedChemExpress and dissolved in DMSO at a stock solution concentration of 10 mM. Epidermal growth factor (EGF), basic fibroblast growth factor (bFGF) and insulin were purchased from PeproTech, Inc.. In addition, 2% B27 was acquired from Gibco; Thermo Fisher Scientific, Inc..

The primary antibodies that were used in the present study, including Shh (cat. no. 20697-1-AP), Gli1 (cat. no. 66905-1-Ig), Gli2 (cat. no. 18989-1-AP), CD44 (cat. no. 15675-1-AP), CD133 (cat. no. 18470-1-AP), aldehyde dehydrogenase 1 family member A1 (ALDH1A1) (cat. no. 15910-1-AP), Oct4 (cat. no. 11263-1-AP), Nanog (cat. no. 14295-1-AP), cyclin D1 (cat. no. 60186-1-Ig), proliferating cell nuclear antigen (PCNA) (cat. no. 10205-2-AP), Bcl-2 (cat. no. 12789-1-AP), Bax (cat. no. 50599-2-Ig), and GAPDH (cat. no. 10494-1-AP) were purchased from ProteinTech, Inc.. Cleaved caspase 3 (cat. no. 9661), cleaved caspase 8 (cat. no. 8592) and cleaved caspase 9 (cat. no. 20750) were obtained from Cell Signaling Technology, Inc.. Smo (cat. no. DF5152) was obtained from Affinity Biosciences, Inc. Anti-rabbit (cat. no. SA00001-2) and anti-mouse (cat. no. SA00001-1) second antibodies were purchased from ProteinTech, Inc..

 Cell culture and sphere formation assay

The renal cancer 786-O and ACHN cell lines were purchased from Type Culture Collection of the Chinese Academy of Sciences and cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.), 100 IU/ml penicillin and 100 µg/ml streptomycin. All cells were cultured at 37°C with 5% CO2.

The 786-O and ACHN cells were washed twice, seeded into a low-attachment plate at a density of 5,000 cells/well, and cultured at 37°C in a humidified incubator with 5% CO2 in serum-free DMEM/F12 (Gibco; Thermo Fisher Scientific, Inc.) containing 4 mg/ml insulin, 20 ng/ml EGF, 20 ng/ml bFGF, B27 (1:50 dilution) and 0.4% BSA (Beyotime Institute of Biotechnology). Half fresh medium was renewed and chemicals (genistein, vismodegib or purmorphamine) were added every other day. Tumor sphere formation was observed and images were captured using a light microscope (Nikon Corporation).

To investigate the effect of genistein and purmorphamine on the tumorsphere formation capacity of renal CSCs, various concentrations of genistein (0, 30, 60 and 90 µM) or purmorphamine (1 µM) were added to each well with 0.1% DMSO as the control. After 5 days treatment at 37°C in a humidified incubator with 5% CO2, the number of tumor spheres in each group with a diameter >50 µm was counted.

 Cell cycle analysis

Following culture in serum-supplemented medium (SSM) or serum-free medium (SFM) for 5 days, 786-O and ACHN cells were collected at a density of 1×106/ml, and then fixed with 75% ice-cold ethanol at −20°C overnight. Subsequently, the cells were washed twice with PBS and treated with 20 mg/ml propidium iodide (PI; Invitrogen; Thermo Fisher Scientific, Inc.), 0.1% Triton X-100 (Invitrogen; Thermo Fisher Scientific, Inc.) and 0.2 mg/ml RNase (PureLink; Thermo Fisher Scientific, Inc.) at room temperature in the dark for 15 min. Subsequently, flow cytometry (FCM) using a FACSCalibur™ flow cytometer (BD Biosciences) was used to analyze the cell cycle phase distribution and the percentage of cells in different phases. The data were analyzed using FlowJo software (v10.0.7; FlowJo LLC).

 Western blotting

786-O and ACHN tumor spheres were harvested and washed with ice-cold PBS. The cell precipitates were homogenized in RIPA buffer (Beyotime Institute of Biotechnology) containing complete protease inhibitors, followed by centrifugation at 15,000 × g for 30 min at 4°C. The supernatants were collected and denatured. BCA protein assay (Pierce; Thermo Fisher Scientific, Inc.) was utilized to determine the concentration of each protein. The proteins (50 µg per lane) were separated via 10% SDS-PAGE and then transferred onto PVDF membranes (EMD Millipore). Subsequently, the PVDF membranes were treated with 5% skimmed milk at room temperature for 2 h and incubated with the primary antibodies against CD133 (1:500 dilution), Gli1 (1:500 dilution), Gli2 (1:500 dilution), CD44 (1:1,000 dilution), ALDH1A1 (1:1,000 dilution), CD44 (1:1,000 dilution), Oct4 (1:1,000 dilution), Nanog (1:1,000 dilution), Bcl2 (1:1,000 dilution), Bax (1:1,000 dilution), cleaved caspase 3 (1:1,000 dilution), cleaved caspase 9 (1:1,000 dilution), cleaved caspase 8 (1:1,000 dilution), cyclin D1 (1:1,000 dilution), PCNA (1:1,000 dilution), Shh (1:1,000 dilution), Smo (1:1,000 dilution), and GAPDH (1:1,000 dilution) at 4°C overnight. Membranes were rinsed and incubated with the corresponding peroxidase-conjugated secondary antibodies (1:5,000 dilution) for 1 h at 25°C. Chemiluminescent detection was performed using an ECL kit (Beyotime Institute of Biotechnology). GAPDH was used as an internal control in order to measure the relative expression of each protein. ImageJ software (v1.46; National Institutes of Health) was used to quantify the protein bands of interest.

 RNA extraction and reverse transcription-quantitative PCR (RT-qPCR)

Total cellular RNA was extracted from renal cancer adherent or tumor sphere cells using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), and subsequently reverse-transcribed into cDNA using 5X All-In-One RT master mix (Applied Biological Materials, Inc.), according to the manufacturer's protocol, as follows: 25°C for 10 min, 42°C for 15 min for cDNA synthesis, then 85°C for 5 min followed by chilling on ice. qPCR was performed using the Power SYBR Green Master mix (Applied Biosystems; Thermo Fisher Scientific, Inc.) and a LC96 real-time PCR system. The amplification reactions were as follows: An initial hold step at 95°C for 5 min and 45 cycles of a two-step PCR (95°C for 15 sec, 54°C for 30 sec and 72°C for 30 sec). GAPDH levels were used as normalization controls. Fold changes in gene expression were calculated using a comparative threshold cycle (Cq) method using the formula 2−ΔΔCT (24). The forward and reverse primers used for qPCR are presented in Table I.

 Detection of apoptotic cells by FCM

The apoptosis assay was performed using a fluorescein isothiocyanate (FITC)-Annexin-V apoptosis detection kit purchased from BD Biosciences. Following treatment with genistein at different concentrations (0, 30, 60 and 90 µM) for 5 days at 37°C with 5% CO2, 786-O tumor spheres were harvested and washed twice with PBS. Subsequently, cells were resuspended with 100 µl binding buffer (BD Biosciences) at a density of 1×106/ml, incubated with Annexin V-fluorescein isothiocyanate (5 µl) and PI (5 µl) at room temperature in the dark for 15 min, and then detected using FACSCalibur™ (BD Biosciences) flow cytometer within 1 h. The data were analyzed using FlowJo software (v10.0.7; FlowJo LLC).

 Immunofluorescence staining

Following genistein treatment for 5 days at 37°C with 5% CO2, the tumor spheres were washed three times and fixed with 4% paraformaldehyde for 15 min at 25°C. The tumor spheres were subsequently washed three times with PBS-Tween 20 (PBST) then blocked with 5% BSA (Beyotime Institute of Biotechnology) for 1 h at 25°C, following which the tumor spheres were incubated with a rabbit CD44 or Smo (1:100 dilution) antibody at 4°C overnight, followed by washing with PBST three times. Subsequently, tumor spheres were stained with Cy3-conjugated goat anti-rabbit secondary antibody (1:1,000 dilution; cat. no. P0173; Beyotime Institute of Biotechnology) for 2 h at 25°C, followed by counterstaining with DAPI for 10 min at 25°C. Images were obtained using a fluorescence microscope (Olympus Corporation) at a magnification of ×100.

 Statistical analysis

Each experiment was repeated three times independently. A two-tailed Student's t-test was used to analyze the statistical differences between two groups. One-way analysis of variance with Tukey post hoc test was utilized for comparisons among multiple groups. The results are presented as the mean ± standard deviation. All analyses were performed using SPSS version 11.0 software (SPSS, Inc.). P<0.05 was considered to indicate a statistically significant difference.

 Results <sec> <title>Tumor sphere formation in renal cancer cells through culture in SFM

A number of studies have reported that CSCs have the ability to grow in suspension and to form spheres through culturing under SFM conditions (10,25,26). Therefore, a tumor sphere formation assay via culturing in SFM is an efficient way to isolate and enrich CSCs. In the present study, 786-O and ACHN cell lines were able to form stable cell spheres following culturing in SFM for 5 days (Fig. 1A). To further elucidate the CSC characteristics of the sphere-forming cells, mRNA and protein expression levels of renal CSC markers, including Nanog, Oct4, ALDH1A1, CD44 and CD133, were detected. Following culturing under SFM conditions for 5 days, the mRNA and protein expression levels of CSC markers were markedly upregulated compared with adherent cells cultured under SSM conditions (Fig. 1B and C). Furthermore, FCM analysis of the cell cycle distribution suggested that the sphere-forming cells were primarily arrested at G0/G1 phase instead of S1 phase, in contrast to the adherent cells (Fig. 1D). These results illustrated the CSC characteristics of the cells cultured under SFM conditions.

 Genistein diminishes the characteristics of renal CSCs

Genistein has been demonstrated to target CSCs in several types of malignancy (20,23,27). In the present study, 786-O and ACHN sphere-forming cells were treated with genistein at different concentrations (0, 30, 60 and 90 µM) for 5 days, in order to investigate whether genistein could exhibit its suppressive effect on renal CSCs. As presented in Fig. 2A and B, the tumor sphere formation assay revealed that genistein-treatment could, in a dose-dependent manner, significantly reduce the number and size of sphere-forming cells in the two cell lines. Following treatment with genistein for 5 days, the mRNA and protein expression levels of renal CSC markers were markedly downregulated in the sphere-forming cells of the two cell lines (Fig. 2C and D). In addition, immunofluorescent staining indicated that the number of CD44-positive 786-O sphere-forming cells was decreased following genistein treatment in a dose-dependent manner (Fig. 2E). Overall, these data revealed that genistein could effectively diminish the characteristics of renal CSCs.

 Genistein inhibits the proliferation and induces the apoptosis of renal CSCs

Furthermore, the effects of genistein on cell proliferation and apoptosis were investigated in the present study. As presented in Fig. 3A, the expression levels of proliferation-associated proteins, including PCNA and cyclin D1, were markedly downregulated in the 786-O and ACHN sphere-forming cells following genistein treatment. Additionally, the expression level of the anti-apoptotic protein Bcl-2 was decreased, while the expression levels of the pro-apoptotic proteins Bax, cleaved caspase 8, cleaved caspase 9 and cleaved caspase 3 were markedly upregulated following genistein-treatment (Fig. 3B). In addition, FCM indicated that genistein could significantly induce apoptosis in ACHN sphere-forming cells (Fig. 3C and D). These results revealed that genistein could inhibit the proliferation and induce the apoptosis of renal CSCs.

 Genistein diminishes renal CSC characteristics by suppressing the Shh pathway

The Shh pathway is understood to be an important regulator of renal CSCs (28–30). In the present study, it was demonstrated that sphere-forming cells treated with 15 µM vismodegib for 5 days, a Smo inhibitor that suppressed Shh activation, exhibited downregulated expression levels of renal CSC markers (Fig. 4A). Additionally, the present study investigated whether genistein could inhibit the Shh pathway in renal CSCs. As presented in Fig. 4B, genistein-treatment resulted in markedly decreased expression levels of the Shh pathway-associated proteins in 786-O and ACHN sphere-forming cells. Furthermore, immunofluorescent staining indicated that the number of Smo-positive 786-O sphere-forming cells decreased following genistein-treatment in a dose-dependent manner (Fig. 4C). These data indicate that genistein may inhibit the Shh pathway in renal CSCs.

In addition, purmorphamine, an activator of Smo that activates the Shh pathway, was used to further determine the role of the Shh pathway in the suppressive effect exerted by genistein on renal CSCs. The results of the present study revealed that purmorphamine could reverse the suppressive effects of genistein on sphere formation (Fig. 4D and E). Additionally, purmorphamine-treatment increased the expression levels of renal CSC markers in 786-O and ACHN sphere-forming cells and reversed the inhibitory effect of genistein on the Shh pathway (Fig. 5A and B). Furthermore, the inhibitory effects of genistein on cell proliferation and apoptosis-associated proteins were reversed following purmorphamine-treatment (Fig. 5C and D). In conclusion, these results indicate a suppressive effect of genistein on renal CSCs via the inhibition of the Shh pathway.

 Discussion

It has been demonstrated that CSCs serve a vital role in cancer development, progression and drug resistance. The Shh signaling pathway has been implicated in maintaining the pluripotency of CSCs. Genistein, a major isoflavone component that is isolated from soybeans and soy products, has been reported to possess anticancer activity (31). The results of the present study suggested that genistein may inhibit the activities of renal CSCs by suppressing the Shh signaling pathway.

The formation of 3D spheres under non-adherent and serum-free conditions is considered to be one of the major characteristics of CSCs (32), and this trait provides a convenient and effective way to isolate and enrich putative CSCs. To date, several markers have been used to distinguish renal CSCs, including CD133, CD44, ALDH1A1, Nanog and Oct4 (6,33). CD133-positive progenitors contribute to tumor angiogenesis, which can notably enhance tumor development and growth when co-transplanted with renal carcinoma cells (9,34). CD44-positive populations derived from 786-O, Caki-1, ACHN and HEK293T renal cancer cells have self-renewal properties and sphere formation capabilities (35,36). In addition, clinical data have demonstrated that CD44 is associated with poor prognosis, cancer cell invasion and metastasis, as well as resistance to sunitinib-treatment (37,38). ALDH1-positive cells are associated with higher sphere-forming ability, self-renewal ability and tumorigenicity compared with their ALDH1-negative counterparts (39). Additionally, aberrant expression of Oct4 and Nanog is considered to be characteristic of the pluripotent stem cells of an embryo and embryonic stem cells, which are involved in maintaining the self-renewal ability and pluripotency of CSCs (40). In the present study, renal CSCs were enriched from the adherent renal cancer cell lines 786-O and ACHN, which exhibited sphere formation capabilities when cultured under SFM conditions. Additionally, the results of the present study indicated that sphere-forming cells cultured under SFM conditions exhibited markedly elevated expression levels of renal CSC markers, including CD133, CD44, ALDH1A1, Oct4 and Nanog. An increasing amount of evidence has suggested that the quiescent stem-like populations may contribute to the formation of CSCs (41,42). In line with the aforementioned findings, the present study also revealed that cells cultured under SFM conditions were more frequently arrested at the G0/G1 phase compared with the adherent cells cultured under SSM conditions. These results illustrated the CSC characteristics of these cells when cultured in SFM.

Genistein, a predominant isoflavone found in soybeans, has multiple anticancer effects in various different types of cancer, including lung, colon, head and neck squamous cell carcinoma, and hepatocellular carcinoma (21,43–45). A previous epidemiological study based on observations made in Asian countries, including China, demonstrated that the incidence rates of breast and prostate cancer are lower than those in the USA and Europe, where diets are lower in soy products (46). Accumulating evidence suggests that genistein exhibits anticarcinogenic effects on CSCs in vivo and in vitro, including in prostate (27), gastric (20) and breast cancer (19). In line with the aforementioned studies, the results of the present study suggested that genistein could efficiently diminish the activity of renal CSCs by repressing tumor sphere formation, downregulating the expression levels of renal CSC markers, and inhibiting the proliferation and inducing the apoptosis of renal CSCs.

The Shh signaling pathway is a major regulator of cell differentiation, cell proliferation and tissue polarity (47). To date, a large amount of evidence has been accumulated that supports the view that the aberrant activation of Shh signaling is involved in tumorigenesis, tumor progression and therapeutic response in several types of cancer, including medulloblastoma, malignant glioma and leukemia, as well as lung, pancreatic, breast and renal cancer (48,49). Behnsawy et al (30) reported that treatment with Shh recombinant, the Shh signaling stimulator, could enhance RCC cell proliferation, whereas treatment with cyclopamine, a Smo inhibitor, could inhibit tumor growth. Qian et al (29) demonstrated that Shh signaling was involved in the stimulation of renal CSC pluripotency, induced by cigarette smoking. Therefore, targeting of the Shh pathway with phytochemicals may provide a potential strategy for intervention in renal cancer. In the present study, genistein could inhibit the activation of the Shh pathways in renal CSCs by downregulating the levels of Shh, Smo, Gli1 and Gli2. By contrast, the purmorphamine-triggered activation of the Shh pathway may abolish the inhibitory effects of genistein on tumor sphere formation, CSC marker expression, and the proliferation and apoptosis of renal CSCs. Collectively, these results demonstrated the interventional effect of genistein on renal CSCs via Shh pathway inhibition. However, the results of the present study are based on in vitro experiments, therefore further in vivo studies are required to validate the role of the Shh signaling pathway in renal CSCs inhibition by genistein. Moreover, additional in vivo studies are also warranted to explore whether genistein inhibits other renal CSC models, such as side population and chemotherapy enrichment.

In conclusion, the present study revealed that genistein exerts an interventional inhibitory effect on renal CSCs by suppressing the Shh pathway, which may provide novel insights into the molecular mechanism of renal CSCs, as well as valuable avenues for investigating potential interventional targets of genistein on renal CSCs.

 Acknowledgements

Not applicable.

 Funding

This study was supported by the Natural Science at Higher Institutions of Anhui Province (grant no. kj2018A0209) and Natural Science Foundation of Anhui Province (grant no. 1608085QH173).

 Availability of data and materials

The analyzed data sets generated during the study are available from the corresponding author on reasonable request.

 Authors' contributions

DY and CZ designed the study. EL, TZ, XS, YL and HG performed the experiments. EL analyzed the data and wrote the manuscript. All authors read and approved the final manuscript for publication.

 Ethics approval and consent to participate

Not applicable.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References ZnaorALortet-TieulentJLaversanneMJemalABrayFInternational variations and trends in renal cell carcinoma incidence and mortalityEur Urol67519530201510.1016/j.eururo.2014.10.00225449206 SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin65529201510.3322/caac.2125425559415 ReyaTMorrisonSJClarkeMFWeissmanILStem cells, cancer, and cancer stem cellsNature414105111200110.1038/3510216711689955 CiardielloCLeoneABudillonAThe crosstalk between cancer stem cells and microenvironment is critical for solid tumor progression: The significant contribution of extracellular vesiclesStem Cells Int20186392198201810.1155/2018/639219830532788 PragerBCXieQBaoSRichJNCancer stem cells: The architects of the tumor ecosystemCell Stem Cell244153201910.1016/j.stem.2018.12.00930609398 LucarelliGGalleggianteVRutiglianoMVavalloADitonnoPBattagliaMIsolation and characterization of cancer stem cells in renal cell carcinomaUrologia824653201510.5301/uro.500009925451878 JiaoXRizvanovAACristofanilliMMiftakhovaRRPestellRGBreast cancer stem cell isolationMethods Mol Biol1406121135201610.1007/978-1-4939-3444-7_1026820950 JensenSSMeyerMPettersonSAHalleBRosagerAMAaberg-JessenCThomassenMBurtonMKruseTAKristensenBWEstablishment and characterization of a tumor stem cell-based glioblastoma invasion modelPLoS One11e0159746201610.1371/journal.pone.015974627454178 BussolatiBBrunoSGrangeCFerrandoUCamussiGIdentification of a tumor-initiating stem cell population in human renal carcinomasFASEB J2236963705200810.1096/fj.08-10259018614581 ZhongYGuanKGuoSZhouCWangDMaWZhangYLiCZhangSSpheres derived from the human SK-RC-42 renal cell carcinoma cell line are enriched in cancer stem cellsCancer Lett299150160201010.1016/j.canlet.2010.08.01320846785 HuangBHuangYJYaoZJChenXGuoSJMaoXPWangDHChenJXQiuSPCancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769PPLoS One8e68293201310.1371/journal.pone.006829323874578 YangLXieGFanQXieJActivation of the hedgehog-signaling pathway in human cancer and the clinical implicationsOncogene29469481201010.1038/onc.2009.39219935712 RuchJMKimEJHedgehog signaling pathway and cancer therapeutics: Progress to dateDrugs73613623201310.1007/s40265-013-0045-z23605693 GorojankinaTHedgehog signaling pathway: A novel model and molecular mechanisms of signal transductionCell Mol Life Sci7313171332201610.1007/s00018-015-2127-426762301 Ruiz i AltabaAMasCSteccaBThe Gli code: An information nexus regulating cell fate, stemness and cancerTrends Cell Biol17438447200710.1016/j.tcb.2007.06.00717845852 ChenYWangXQZhangQZhuJYLiYXieCFLiXTWuJSGengSSZhongCYHanHY(−)-Epigallocatechin-3-gallate inhibits colorectal cancer stem cells by suppressing Wnt/β-catenin pathwayNutrients9E572201710.3390/nu906057228587207 ZhuJWangSChenYLiXJiangYYangXLiYWangXMengYZhuMmiR-19 targeting of GSK3beta mediates sulforaphane suppression of lung cancer stem cellsJ Nutr Biochem448091201710.1016/j.jnutbio.2017.02.02028431267 LiXWangXXieCZhuJMengYChenYLiYJiangYYangXWangSSonic hedgehog and Wnt/beta-catenin pathways mediate curcumin inhibition of breast cancer stem cellsAnticancer Drugs29208215201829356693 FanPHFanSJWangHMaoJShiYIbrahimMMMaWYuXHouZWangBLiLGenistein decreases the breast cancer stem-like cell population through Hedgehog pathwayStem Cell Res Ther4146201310.1186/scrt35724331293 YuDShinHSLeeYSLeeDKimSLeeYCGenistein attenuates cancer stem cell characteristics in gastric cancer through the downregulation of Gli1Oncol Rep31673678201410.3892/or.2013.289324297371 ZhangYChenHGenistein attenuates WNT signaling by up-regulating sFRP2 in a human colon cancer cell lineExp Biol Med (Maywood)236714722201110.1258/ebm.2011.01034721571909 AntosiakAMilowskaKMaczynskaKRozalskaSGabryelakTCytotoxic activity of genistein-8-C-glucoside form Lupinus luteus L. and genistein against human SK-OV-3 ovarian carcinoma cell lineMed Chem Res266473201710.1007/s00044-016-1725-528111515 HuangWWanCLuoQHuangZLuoQGenistein-inhibited cancer stem cell-like properties and reduced chemoresistance of gastric cancerInt J Mol Sci1534323443201410.3390/ijms1503343224573253 LivakKJSchmittgenTDAnalysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) methodMethods25402408200110.1006/meth.2001.126211846609 HouseCDHernandezLAnnunziataCMIn vitro enrichment of ovarian cancer tumor-initiating cellsJ Vis ExpFeb182015doi: 10.3791/5244610.3791/5244625742116 PozziVSartiniDRocchettiRSantarelliARubiniCMorgantiSGiulianteRCalabreseSDi RuscioGOrlandoFIdentification and characterization of cancer stem cells from head and neck squamous cell carcinoma cell linesCell Physiol Biochem36784798201510.1159/00043013826021266 ZhangLLiLJiaoMWuDWuKLiXZhuGYangLWangXHsiehJTHeDGenistein inhibits the stemness properties of prostate cancer cells through targeting Hedgehog-Gli1 pathwayCancer Lett3234857201210.1016/j.canlet.2012.03.03722484470 DormoyVDanilinSLindnerVThomasLRothhutSCoquardCHelwigJJJacqminDLangHMassfelderTThe sonic hedgehog signaling pathway is reactivated in human renal cell carcinoma and plays orchestral role in tumor growthMol Cancer8123200910.1186/1476-4598-8-12320015350 QianWKongXZhangTWangDSongJLiYLiXGengHMinJKongQCigarette smoke stimulates the stemness of renal cancer stem cells via Sonic Hedgehog pathwayOncogenesis724201810.1038/s41389-018-0029-729540668 BehnsawyHMShigemuraKMeligyFYYamamichiFYamashitaMHaungWCLiXMiyakeHTanakaKKawabataMPossible role of sonic hedgehog and epithelial-mesenchymal transition in renal cell cancer progressionKorean J Urol54547554201310.4111/kju.2013.54.8.54723956832 MukundVMukundDSharmaVMannarapuMAlamAGenistein: Its role in metabolic diseases and cancerCrit Rev Oncol Hematol1191322201710.1016/j.critrevonc.2017.09.00429065980 TirinoVDesiderioVPainoFDe RosaAPapaccioFLa NoceMLainoLDe FrancescoFPapaccioGCancer stem cells in solid tumors: An overview and new approaches for their isolation and characterizationFASEB J271324201310.1096/fj.12-21822223024375 CorroCMochHBiomarker discovery for renal cancer stem cellsJ Pathol Clin Res4318201810.1002/cjp2.9129416873 ParkEKLeeJCParkJWBangSYYiSAKimBKParkJHKwonSHYouJSNamSWTranscriptional repression of cancer stem cell marker CD133 by tumor suppressor p53Cell Death Dis6e1964201510.1038/cddis.2015.31326539911 LuJCuiYZhuJHeJZhouGYueZBiological characteristics of Rh123high stem-like cells in a side population of 786-O renal carcinoma cellsOncol Lett519031908201310.3892/ol.2013.127023833664 DebebBGZhangXKrishnamurthySGaoHCohenELiLRodriguezAALandisMDLucciAUenoNTCharacterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cellsMol Cancer9180201010.1186/1476-4598-9-18020615238 LichnerZSalehCSubramaniamVSeivwrightAPrud'hommeGJYousefGMmiR-17 inhibition enhances the formation of kidney cancer spheres with stem cell/ tumor initiating cell propertiesOncotarget655675581201510.18632/oncotarget.190125011053 MikamiSMizunoRKosakaTSayaHOyaMOkadaYExpression of TNF-α and CD44 is implicated in poor prognosis, cancer cell invasion, metastasis and resistance to the sunitinib treatment in clear cell renal cell carcinomasInt J Cancer13615041514201510.1002/ijc.2913725123505 UedaKOgasawaraSAkibaJNakayamaMTodorokiKUedaKSanadaSSuekaneSNoguchiMMatsuokaKYanoHAldehyde dehydrogenase 1 identifies cells with cancer stem cell-like properties in a human renal cell carcinoma cell linePLoS One8e75463201310.1371/journal.pone.007546324116047 KhanMICzarneckaAMHelbrechtIBartnikELianFSzczylikCCurrent approaches in identification and isolation of human renal cell carcinoma cancer stem cellsStem Cell Res Ther6178201510.1186/s13287-015-0177-z26377541 WuFHMuLLiXLHuYBLiuHHanLTGongJPCharacterization and functional analysis of a slow-cycling subpopulation in colorectal cancer enriched by cell cycle inducer combined chemotherapyOncotarget87846678479201729108242 GiancottiFGMechanisms governing metastatic dormancy and reactivationCell155750764201310.1016/j.cell.2013.10.02924209616 TianTLiJLiBWangYLiMMaDWangXGenistein exhibits anti-cancer effects via down-regulating FoxM1 in H446 small-cell lung cancer cellsTumour Biol3541374145201410.1007/s13277-013-1542-024379139 LiSLiJDaiWZhangQFengJWuLLiuTYuQXuSWangWGenistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell deathBr J Cancer11715181528201710.1038/bjc.2017.32328926527 ArditoFDi GioiaGPellegrinoMRMuzioLLGenistein as a potential anticancer agent against head and neck squamous cell carcinomaCurr Top Med Chem18174181201810.2174/156802661866618011612265029345579 SpagnuoloCRussoGLOrhanIEHabtemariamSDagliaMSuredaANabaviSFDeviKPLoizzoMRTundisRNabaviSMGenistein and cancer: Current status, challenges, and future directionsAdv Nutr6408419201510.3945/an.114.00805226178025 Ruiz i AltabaAHedgehog signaling and the Gli code in stem cells, cancer, and metastasesSci Signal4pt9201110.1126/scisignal.200254022114144 RimkusTKCarpenterRLQasemSChanMLoHWTargeting the sonic Hedgehog signaling pathway: Review of smoothened and GLI inhibitorsCancers (Basel)8E22201610.3390/cancers802002226891329 D'AmatoCRosaRMarcianoRD'AmatoVFormisanoLNappiLRaimondoLDi MauroCServettoAFulcinitiFInhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cellsBrit J Cancer11111681179201410.1038/bjc.2014.42125093491

Tumor sphere-formation assay. 786-O and ACHN cells were cultured in SSM and SFM for 5 days. (A) Cell images were captured using a light microscope. Scale bar, 100 µm. (B) Reverse transcription-quantitative PCR was used to analyze the mRNA levels of renal CSC markers, including CD133, CD44, ALDH1A1, Oct4 and Nanog. (C) Western blotting was used to quantitatively measure the expression levels of corresponding renal CSC markers. (D) Flow cytometry was used to assess cell cycle phase distribution. Data are presented as the mean ± standard deviation from three independent experiments. **P<0.01 vs. SSM. ALDH1A1, aldehyde dehydrogenase 1 family member A1; CSC, cancer stem cell; SFM, serum-free medium; SSM, serum-supplemented medium.

Genistein diminishes renal CSC characteristics. 786-O and ACHN sphere-forming cells were treated with different concentrations of genistein (0, 30, 60 and 90 µM) for 5 days. (A) Representative images. Scale bar, 100 µm. (B) Numbers of tumor spheres were counted and normalized to the control group. (C) mRNA expression levels of renal CSC markers were measured by reverse transcription-quantitative PCR. (D) Corresponding protein expression levels of renal CSCs markers were measured by western blotting. (E) Immunofluorescence staining images of 786-O tumor spheres were captured to determine CD44 expression. Scale bar, 100 µm. Data are presented as the mean ± standard deviation from three independent experiments. *P<0.05, **P<0.01 vs. genistein 0 µM. ALDH1A1, aldehyde dehydrogenase 1 family member A1; CSC, cancer stem cell.

Genistein inhibits the proliferation and induces the apoptosis of renal CSCs. 786-O and ACHN sphere-forming cells were treated with different concentrations of genistein (0, 30, 60 and 90 µM) for 5 days. Western blotting was used to analyze the expression levels of various (A) proliferation-associated (PCNA and cyclin D1) and (B) apoptosis-associated (Bcl-2, Bax, cleaved caspase 8, cleaved caspase 9 and cleaved caspase 3) proteins. Apoptotic populations among ACHN sphere-forming cells were detected using flow cytometry. (C) Representative images. (D) Percentage of apoptotic cells among ACHN sphere-forming cells. Data are presented as the mean ± standard deviation from three independent experiments. *P<0.05, **P<0.01 vs. genistein 0 µM. CSC, cancer stem cell; PCNA, proliferating cell nuclear antigen.

Genistein blocks the activity of the Shh pathway. (A) 786-O and ACHN sphere-forming cells were treated with the Smo inhibitor vismodegib (15 µM) for 5 days, and the expression levels of renal CSC markers were assessed by western blotting. (B) 786-O and ACHN sphere-forming cells were treated with different concentrations of genistein (0, 30, 60 and 90 µM) for 5 days. The expression levels of critical components of the Shh pathway were measured by western blotting. (C) Immunofluorescence staining images of 786-O tumor spheres were captured to determine Smo expression. Scale bar, 100 µm. (D) 786-O and ACHN sphere-forming cells were treated with 90 µM genistein in the presence or absence of 1 µM purmorphamine for 5 days. Representative images of sphere-forming cells. Scale bar, 100 µm. (E) Numbers of sphere-forming cells were counted and normalized to the control group (genistein 0 µM and purmorphamine 0 µM). *P<0.05, **P<0.01 vs. genistein 0 µM. ##P<0.01 vs. genistein 90 µM. ALDH1A1, aldehyde dehydrogenase 1 family member A1; CSC, cancer stem cell; Gli, glioma-associated oncogene; Shh, sonic hedgehog; Smo, smoothened.

Genistein diminishes renal CSC characteristics by suppressing the Shh pathway. 786-O and ACHN sphere-forming cells were treated with 90 µM genistein in the presence or absence of 1 µM purmorphamine for 5 days. (A) Western blot analysis of renal CSC markers. (B) Western blot analysis of the critical components of the Shh pathway. Western blotting was used to analyze the expression levels of (C) proliferation-associated proteins (PCNA and cyclin D1) and (D) apoptosis-associated proteins (Bcl-2, Bax, cleaved caspase 8, cleaved caspase 9 and cleaved caspase 3). *P<0.05, **P<0.01 vs. genistein 0 µM. #P<0.05, ##P<0.01 vs. genistein 90 µM. ALDH1A1, aldehyde dehydrogenase 1 family member A1; CSC, cancer stem cell; Gli, glioma-associated oncogene; PCNA, proliferating cell nuclear antigen; Shh, sonic hedgehog; Smo, smoothened.

Oligonucleotide sequences of primers for reverse transcription-quantitative PCR.

Genes Forward (5′-3′) Reverse (5′-3′)
CD133 TACAACGCCAAACCACGACTGT TCTGAACCAATGGAATTCAAGACCCTTT
CD44 AGCAACCAAGAGGCAAGAAA GTGTGGTTGAAATGGTGCTG
ALDH1A1 GCACGCCAGACTTACCTGTC CCTCCTCAGTTGCAGGATTAAAG
Oct4 GACAACAATGAAAATCTTCAGGAGA TTCTGGCGCCGGTTACAGAACCA
Nanog TTTGTGGGCCTGAAGAAAACT AGGGCTGTCCTGAATAAGCAG
GAPDH GACTGTGGATGGCCCCTCCGG AGGTGGAGGAGTGGGTGTCGC

ALDH1A1, aldehyde dehydrogenase 1 family member A1.